Changchun Genescience Pharmaceutical Co., Ltd.

This study tests a new medicine called GenSci134 in 128 children with growth hormone deficiency, a condition where the body doesn't make enough growth hormone, leading to slow growth. The study has two parts: first, a small group will get a single dose to check safety; second, a …

This study tests a new drug, GenSci048, in people with active non-infectious uveitis, an inflammatory eye disease. The trial will compare two doses of GenSci048 against a placebo to see if it can control the disease and reduce treatment failure. About 111 adults with active uveit…

This study tests a new oral medicine (GS3-007a) for children with growth hormone deficiency who have not yet received any growth treatment. In the first part, different doses are compared to a placebo over 14 days to find a safe dose. In the second part, the chosen dose is compar…

This early-stage trial tests a new drug called GenSci142 in 30 healthy Chinese women to see if it is safe and how the body processes it. Participants receive a single dose of the drug or a placebo, and are monitored for side effects for 15 days. The goal is to gather safety infor…

This study tests a new medicine called GenSci134 in 128 children with idiopathic short stature (short height with no known cause). The goal is to see if it is safe and helps children grow faster compared to a standard growth hormone. The study has two parts: first, a single dose …

This study looks at a fertility drug called corifollitropin alfa in women aged 36 to 40 who are doing IVF. The goal is to see if the drug is safe and helps produce eggs. Researchers will track side effects and pregnancy rates over one year.

This study looks at whether adding a special form of megestrol acetate to standard treatment can help improve appetite and body weight in people with advanced liver cancer who are experiencing cachexia (severe weight loss and muscle wasting). About 68 participants will be randoml…

This early-stage study tests the safety of a new drug called GenSci155 in 68 healthy adults aged 18 to 60. Participants receive either the drug or a placebo by IV, and researchers monitor side effects and how the drug moves through the body. The goal is to gather safety informati…

This early-stage study looks at how the drug GS1-144 moves through the bodies of women with and without liver problems. About 24 women aged 18 to 70 will take part. The goal is to measure drug levels and see if liver function affects them. No treatment is being tested.